Article

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancer

2022-05-10

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Purpose</h4> Novel covalent inhibitors of KRAS G12C have shown limited response rates in KRAS G12C mutant (MT) colorectal cancer (CRC) patients. Thus, novel KRAS G12C inhibitor combination strategies that can achieve deep and durable responses are needed. <h4>Experimental design</h4> Small molecule KRAS G12C inhibitors AZ’1569 and AZ’8037 were employed. To identify novel candidate com...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9f7b9331-2780-58fc-8cf7-2ab9697fdea6
DOI: 10.1101/2022.05.10.491367

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerDOI 10.1101/2022.05.10.491367Read

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Semantic proximity Read

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Semantic proximity Read

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity Read

Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL‑XLSemantic proximity Read

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity Read

Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response.Semantic proximity Read

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity Read

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancerSemantic proximity Read

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCSemantic proximity Read

The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.Semantic proximity Read

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationSemantic proximity Read